Special Issue

New Platforms for Cancer Treatment—Emerging Advances

Message from the Guest Editors

Nanotechnology has emerged as a more selective option for cancer treatment. It offers targeted therapy, biodistribution, and reduced toxicity. Another strategy for advancing cancer treatment is based on gene therapy, including DNA microRNAs, oncolytic virotherapy, and gene-directed enzyme pro-drug deliveries. Efforts to discover new active molecules or novel combinations continue as a strong branch of cancer treatment novelty. Photodynamic (PDT) and photothermal (PTT) cancer therapies are emerging as new options for the counterpart mutilation of organs and tissues. Monoclonal antibodies have been used to target nanostructures loaded with different drugs to tumoral areas in the human body with success. The scope of this Special Issue includes the following:

- Novel drugs or active compounds for cancer treatment:
- Nanostructures applied to cancer treatment;
- Use of photodynamics and photothermal agents in nanotheranostics;
- Targeting approaches to improve selectivity in cancer;
- Biopharmaceutical studies of antitumoral drugs associated with nanodevices;
- Reviews of current and up-to-date research in cancer treatment and new strategies.

Guest Editors

Dr. Fernanda Karoline Vieira da Silva Torchelsen

Dr. Maria Alice de Oliveira

Dr. Renata Tupinambá Branquinho

Prof. Dr. Vanessa Carla Furtado Mosqueira

Deadline for manuscript submissions

10 December 2025



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/204823

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

